VISINE L.R.
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VISINE L.R. (VISINE L.R.).
Selective alpha-1 adrenergic receptor agonist; constricts conjunctival blood vessels via stimulation of alpha-1 adrenoreceptors in the ophthalmic artery, reducing redness and edema.
| Metabolism | Metabolized primarily by hepatic monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT); systemic absorption is minimal. |
| Excretion | Primarily renal excretion of unchanged drug and metabolites; ~90% of an oral dose is excreted in urine within 24 hours; biliary/fecal excretion accounts for <5%. |
| Half-life | Terminal elimination half-life is 2.1 ± 0.2 hours for the racemic mixture; clinical context: dosing intervals typically every 4-6 hours. |
| Protein binding | <5% bound to plasma proteins (albumin). |
| Volume of Distribution | Vd approximately 0.2 L/kg; indicates limited extravascular distribution. |
| Bioavailability | Ocular topical: systemic bioavailability is very low (<1%) due to local vasoconstriction and minimal absorption; oral bioavailability ~10% due to first-pass metabolism. |
| Onset of Action | Ocular topical: vasoconstriction occurs within minutes; peak effect at 15-30 minutes. |
| Duration of Action | Duration of vasoconstriction is 4-6 hours following topical ocular administration; clinical note: prolonged use may lead to rebound hyperemia. |
| Molecular Weight | 200.67 |
1 to 2 drops in the affected eye(s) every 8 to 12 hours, not to exceed 2 drops per eye every 8 hours. Ophthalmic solution 0.05%.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for GFR changes. Excretion of oxymetazoline is renal, but systemic absorption is minimal. |
| Liver impairment | No specific dose adjustment for Child-Pugh class A, B, or C. Use with caution in severe hepatic impairment due to potential for systemic effects. |
| Pediatric use | Children 6 years and older: 1 drop in affected eye(s) every 8 hours as needed. Not recommended for children under 6 years due to risk of systemic toxicity. |
| Geriatric use | Use same as adult dosing. Monitor for increased systemic absorption due to age-related ocular surface changes and potential for cardiovascular effects (e.g., hypertension, tachycardia). |
| 1st trimester | Limited data; no known teratogenicity in animal studies, but use only if clearly needed. |
| 2nd trimester | Use with caution; may cause maternal hypertension or fetal hypoxia due to vasoconstriction. |
| 3rd trimester | Avoid near term due to risk of neonatal hypotension, bradycardia, or apnea from systemic absorption. |
Clinical note
Comprehensive clinical and safety monograph for VISINE L.R. (VISINE L.R.).
| Placental transfer | Likely minimal due to low systemic bioavailability from ocular administration; however, tetrahydrozoline can cross the placenta if absorbed systemically. |
| Breastfeeding | Excretion into breast milk is unknown; however, low systemic absorption suggests minimal risk. Monitor infant for signs of sympathomimetic effects (irritability, tachycardia). |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to tetrahydrozoline or any componentNarrow-angle glaucomaChildren under 6 years
| Precautions | Avoid use in patients with narrow-angle glaucoma or known hypersensitivity to oxymetazoline; discontinue if ocular pain, vision changes, or headache occur; prolonged use may cause rebound hyperemia; use caution in patients with cardiovascular disease (e.g., hypertension, arrhythmias) or hyperthyroidism; not for use in children under 6 years. |
| Food/Dietary | None known. No clinically relevant food interactions reported. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L3 |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Based on limited human data, no increased risk of major birth defects or miscarriage has been observed with ophthalmic oxymetazoline. However, systemic absorption is minimal, and the risk is considered low. Use only if clearly needed. |
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. Monitor for any ocular adverse effects or systemic effects (e.g., hypertension, tachycardia) if used excessively. |
| Fertility Effects | No studies on fertility effects. No known impact on fertility or reproduction. |
| Visine L.R. contains oxymetazoline, an alpha-adrenergic agonist that causes vasoconstriction of conjunctival blood vessels. Onset within minutes, duration up to 6 hours. Rebound hyperemia upon discontinuation; limit use to 3 days. Contraindicated in narrow-angle glaucoma. Use with caution in patients with hypertension, hyperthyroidism, or CV disease; systemic absorption may occur. |
| Patient Advice | Do not use for more than 3 days to avoid rebound redness. · Remove contact lenses before instillation; wait 15 minutes before reinserting. · Do not share the bottle to prevent infection. · Do not touch bottle tip to eye or any surface. · If symptoms persist or worsen, discontinue use and consult a doctor. · May cause temporary stinging, blurred vision, or headache. |